Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00296
|
|||||
| Drug Name |
Zidovudine
|
|||||
| Synonyms |
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; 3′-Azido-3′-deoxythymidine; 3' Azido 2',3' Dideoxythymidine; 3' Azido 3' deoxythymidine; 3'-Azido-2',3'-Dideoxythymidine; 3'-Azido-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; 3'-Azido-3'-deoxythymidine (AIDS); 3'-Azido-3'deoxythymidine & Interferon-alpha; 3'-Azidothymidine; 3'-Deoxy-3'-azidothymidine; 3'-azido-3'-deoxythymidine, AZT; 3-Azido-3-deoxythymidine; AZT; AZT & CD4(178)-PE 40; AZT & Colony-stimulating factor 2; AZT & Concanavalin A (ConA); AZT & EPO; AZT & GM-CSF; AZT & HPA; AZT & IFN-alpha; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Interferon-.alpha.-2; AZT & Li & EPO; AZT & Li & GM-CSF; AZT & Li & IL-1; AZT & Li & IL-6; AZT & Lymphoblastoid Interferon; AZT & NP (from PHCA or HSA); AZT & PM-19; AZT & SST; AZT & rIFN.alpha.2; AZT & rsCD4 & rIFN.alpha.A; AZT & rsT4; AZT & sCD4; AZT & srCD4; AZT (Antiviral); AZT Antiviral; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; AZT+PRO 140; AZT, Antiviral; Antiviral; Antiviral AZT; Apo-Zidovudine; Azidodeoxythymidine; Azidothymidine; Aztec; BW A509U; BW-A 509U; BW-A-509U; BW-A509U; BWA 509U; BWA-509U; BWA509U; Cpd S; DRG-0004; DS-4152 & AZT; Interferon AD + 3'-azido-3'-deoxythymidine; Intron A & AZT; K7 [P Ti2 W10 O40]; Liposomal AZT-SN-1; Liposomal AZT-SN-3; Met-SDF-1.beta. & AZT; Met-SDF-1.beta. & Zidovudine; Novo-Azt; PC-SOD+AZT;RIFN-beta seron & AZT; Propolis+AZT; Racemic Liposomal AZT; Racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); Retrovir; Retrovir (TN); Retrovir(TM); Retrovis (TN); SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); ZDV; ZIDOVUDINE [AZT]; ZVD; Zidovudin; Zidovudina; Zidovudina [Spanish]; Zidovudine (JAN/USP/INN); Zidovudine EP III; Zidovudine [USAN:INN:BAN:JAN]; Zidovudine+PRO 140; Zidovudinum; Zidovudinum [Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Human immunodeficiency virus infection [ICD11: 1C62.Z] | Approved | [1] | |||
| Therapeutic Class |
Anti-HIV Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H13N5O4
|
|||||
| Canonical SMILES |
CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-]
|
|||||
| InChI |
InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
|
|||||
| InChIKey |
HBOMLICNUCNMMY-XLPZGREQSA-N
|
|||||
| CAS Number |
CAS 30516-87-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 267.24 | Topological Polar Surface Area | 93.2 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
0
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11335699
, 11360938
, 11364242
, 11366804
, 11369366
, 11372752
, 11373842
, 11377528
, 11461910
, 11484570
, 11488743
, 11491322
, 11492147
, 11495162
, 12013681
, 12146009
, 14799161
, 595886
, 596433
, 596437
, 596594
, 596595
, 597291
, 597292
, 597293
, 597457
, 597458
, 597459
, 597460
, 597461
, 597462
, 597463
, 597555
, 597641
, 597664
, 597665
, 600904
, 601536
, 602048
, 622272
, 624122
, 643735
, 644084
, 7846195
, 7847479
, 7980906
, 8149829
, 8173993
, 855980
, 9419
|
|||||
| ChEBI ID |
CHEBI:10110
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [3] | ||
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [4] | ||
| OAT2 | Transporter Info | Organic anion transporter 2 | Substrate | [4] | ||
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [4] | ||
| OAT4 | Transporter Info | Organic anion transporter 4 | Substrate | [4] | ||
| OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OAT1 | Transporter Info | Km = 45.9 microM | Proximal tubule (S2) cells-OAT1 | [4] | |
| OAT2 | Transporter Info | Km = 26.8 microM | Proximal tubule (S2) cells-OAT2 | [4] | ||
| OAT3 | Transporter Info | Km = 145 microM | Proximal tubule (S2) cells-OAT3 | [4] | ||
| OAT4 | Transporter Info | Km = 152 microM | Proximal tubule (S2) cells-OAT4 | [4] | ||
| References | ||||||
| 1 | Zidovudine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 4 | Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. | |||||
| 5 | The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.